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920 Zhou et al April 2014DISCUSSIONDr David L. Dawson (Sacramento, Calif). The use of endo-
vascular techniques for the treatment of abdominal aortic aneu-
rysms continues to develop, 14 years after the introduction of
the ﬁrst commercially produced systems for EVAR. It’s estimated
that more than 75% of treated aneurysms in the U.S. are now
managed with endovascular therapies.
Dr Zhou and her collaborators are to be commended for their
interesting and relevant study of late endoleaks after EVAR, which
was well presented.
We need to hear this information. The Society for Vascular
Surgery clinical practice guidelines for management of aortic aneu-
rysm, published in 2009, considered the available literature, but
many recommendations still lacked speciﬁcity and strength of
evidence, and the Society for Vascular Surgery cited the need for
ongoing study of outcomes and best practices with regard to
post-EVAR follow up.
This study reinforces a principal of vascular care that is well
recognized but inconsistently practiceddthe need for long-term
imaging follow-up after EVAR. The absence of an endoleak during
the ﬁrst year after EVAR is not a reliable predictor of a problem-
free future. This study found that slightly more than half of the
endoleaks seen during follow-up were delayeddthat is, when
endoleaks were detected more than a year after EVAR, it was
most common to have had a prior study that suggested all was well.
This study is of modest size, but it offers a representative
assessment of post-EVAR care in health care system that has the
means to provide ongoing follow-up without economic burden
to the patients; 180 patients were evaluated from 11 years of clin-
ical practice at the Palo Alto VA. It appears that follow-up was
regular for these veterans. This is in contrast to the patients from
the university hospital experience presented to this Society in
2012 at the Stein Erickson Lodge by the OHSU group. In the
Oregon experience, there were 157 patients who needed long-
term follow-up, but 48%–nearly halfdwere lost to follow-up.
Importantly, there was a 31% late complication rate in the patients
that were followed and a 21% reintervention rate for post-EVAR
patients in the series reported last year.
I have two questions for Dr Zhou: ﬁrst, what factors led to the
development of the 12 late type I endoleaks detected in this series?
Andy Schanzer’s 2012 paper in Circulation examined factors that
were associated with risk of aneurysm enlargement after EVAR,
identifying age $80 years, neck diameter $28 mm, neck angula-
tion >60 degrees, and common iliac artery diameter >20 mm.
It appeared that only 25% of type I endoleaks in the presented
series were in octogenarians. Were the others in patients with
adverse neck anatomy? Did graft choice seem to make a difference?
Dr Wei Zhou. Thank you for a very insightful observation.
There were a total of ﬁve type Ia and six type Ib endoleaks. All
patients with type Ia endoleaks had hostile neck conﬁgurations,
but most of the patients who developed type Ib endoleaks had
a relatively straight forward aneurysmal anatomy, which raisesthe concern for long-term iliac artery remodeling and highlights
the necessity for lifelong follow-ups. Most of the patients with
type I endoleaks had Zenith grafts. However, Zenith endograft
was the only graft with suprarenal ﬁxation for a long time. It is
not surprise that Zenith was chosen for patients with difﬁcult
anatomy. We can not say that this particularly graft is associated
with type I endoleak. Patient anatomy should also be considered.
Dr Dawson. Second, what new perspectives can you share
about how to deal with type II endoleaks? You saw isolated type
II endoleaks in 34 of your 180 subjectsda 19% incidence. Is
this number high? A systematic review published this year in the
British Journal of Surgery looked at pooled results from 32 pub-
lished studies involving 21,744 EVAR patients. Type II endoleaks
were reported in 1515 (10.2% of EVARs) and 35% resolved spon-
taneously. How many of the type II endoleaks in your series
resolved completely and permanently without intervention? In
the British review, 29% of interventions for type II endoleaks
were unsuccessful and they found transarterial embolization was
less likely to be successful than techniques with a direct translum-
bar approach. What do you think works most reliably?
To close, I think your observations are interesting and useful
to vascular surgeons. I appreciate the opportunity to have reviewed
your paper. Thank you.
Dr Zhou. I believe that the number of isolated type II endo-
leaks is higher if we consider all patients and have adequate follow-
ups. Most studies showed that type II endoleaks developed early,
but the follow-up length is very limited. Some have showed that
more than 50% of patients are lost to follow-up after endovascular
intervention and more than 30% of patients lost to follow-up
within 2 years of EVAR outside clinical trials. The delayed type
II endoleaks identiﬁed in our study developed at a mean duration
of 30 months following endograft implantation. Without adequate
follow-ups, the type II endoleak reported is grossly underesti-
mated. In our study, we exclude the patient who had less than
1-year follow-up and therefore some of the immediate type II
endoleaks. Our number would be higher if we included immediate
type II endoleaks.
As for intervention, 30% of our patients who underwent type
II endoleak interventions received multiple interventions. As
vascular surgeons, we tend to be more comfortable with transarte-
rial embolization. However, transarterial embolization can be
cumbersome and extremely challenging. Patients who received
multiple interventions in our cohort all originally had a transarterial
approach. Similar to others, we observe higher success rate using
a liquid embolic material through a direct tranlumbar sac puncture
technique. In fact, CT-guided translumbar direct sac embolization
has become the preferred techniques for lumbar artery-related type
II endoleaks in our practice. I prefer to perform the procedure
under a CT guidance in a hybrid room with a combined CT
scanner and a ﬁxed C-arm, but the dynaCT function in modern
angio suites can also help to target nidus for embolization.
